QNRX Quoin Pharmaceuticals, Ltd. Insider Trading

Director LANGER DENNIS buys 15,152 shares of QNRX at $8.49; holdings surge from 1 to 15,153 shares.

LANGER DENNIS, a director at Quoin Pharmaceuticals, purchased 15,152 shares at $8.49 on 2025-10-14, expanding his position from 1 share to 15,153 shares (+1515200.0% net change). The purchase occurred at a price 44.3% below the current price of $15.27, and coincides with a 30-day price surge of +95.3%, suggesting the director established a meaningful stake well ahead of recent momentum. The transaction signals a material commitment from a board member despite the company's unprofitable state (net income of $-3.7M in the most recent full fiscal year), indicating directional confidence in the company's direction despite current financial headwinds. This substantial position increase by an insider warrants monitoring alongside the company's path to profitability.

CFO Dunn Gordon buys 122,221 QNRX shares at $0.45; holdings rise 423.6% on 5 prior well-timed buys at this ticker, cluster pattern active.

Dunn Gordon, CFO of Quoin Pharmaceuticals, purchased 122,221 shares at $0.45 on 2024-12-23, increasing his holdings by 423.6% from 28,856 to 151,077 shares. This buy occurs within a cluster: 3 other insiders also purchased within the past 14 days. More notably, Gordon's prior 5 open-market buys at QNRX were all well-timed, each generating positive 90-day returns ranging from +2900.0% to +3745.1%. His cross-ticker track record shows a 100% win rate on 90-day returns averaging +3387.2%. The current stock price of $19.25 is -89.3% from its 52-week high of $180.14, and the company reported a net loss of $-2,349,885.00 over the most recent full fiscal year. The confluence of a large concentrated buy by an executive with a documented history of well-timed accumulation at this specific ticker, combined with synchronized buying by other insiders, warrants investor attention to understand Gordon's rationale and to monitor whether this price action represents a reversal signal or reflects upcoming catalysts.

CEO Myers buys 555,556 shares at $0.45 for $250,000.20; stock down 89.3% from 52-week high; cluster buy pattern detected

Myers Michael, CEO of QNRX, purchased 555,556 shares at $0.45 on 2024-12-23, expanding his holdings by 1175.7% from 47,252 to 602,808 shares—a substantial concentration increase at a price 89.3% below the 52-week high of $180.14. His prior four purchases at QNRX all generated positive 90-day returns (ranging from 3494.8% to 4271.0%), establishing a pattern of well-timed entry points at this ticker. The company is currently unprofitable with net income of -$2,349,885.00 over its most recent full fiscal year, and this buy is part of a broader cluster pattern with 3 other insiders also purchasing within the past 14 days. The convergence of extreme price weakness, the CEO's significant position increase, his demonstrated track record of well-timed purchases at QNRX, and coordinated insider accumulation warrant close examination of the fundamental catalyst that may have prompted this coordinated action.

COO Carter buys 555.6K shares of QNRX at $0.45, increasing stake by +1179.7%, amid cluster activity and 100% prior win rate.

Carter Denise P. (COO) purchased 555,556 shares at $0.45, escalating her holdings from 47,092 to 602,648 shares—a +1179.7% increase in position size. This transaction occurred within a 14-day cluster window during which 3 other insiders also bought, suggesting aligned confidence among leadership. Notably, Carter's prior 4 trades at QNRX produced an average 90-day return of +3500.9%, with 100% of those trades rising over 90 days—a pattern of consistently well-timed entry points. However, context is critical: the company reported a negative net income of $-2,349,885.00 over its most recent fiscal year, and the stock is currently $19.25, down 89.3% from its 52-week high of $180.14, raising material questions about fundamentals that transcend the favorable historical return metrics.

Director Culverwell bought 100,000 shares of QNRX at $0.45; holds 100,317 post-transaction (+31545.7% vs prior). Cluster buy.

Anthony James Culverwell, a Director at Quoin Pharmaceuticals, purchased 100,000 shares at $0.45 on 2024-12-23, expanding his position from 317 shares to 100,317 shares—a 31545.7% increase. The stock now trades at $19.25, down -89.3% from its 52-week high of $180.14, and has declined -8.2% over the past 30 days despite a 90-day positive return of +7.0%. This acquisition occurs within a broader cluster pattern: 3 other insiders also purchased shares within the past 14 days. While the company reported a full-year net income of $-2.3M (unprofitable), the coordinated insider activity across multiple directors during a period of significant price depreciation from the 52-week high warrants close examination of the underlying drivers and any material developments that may not yet be fully reflected in current pricing.

CFO Dunn Gordon purchases 28,856 shares of QNRX across 5 transactions (Sept 9-10) at blended $0.80, joining cluster of 2 other insider buyers

Dunn Gordon, Chief Financial Officer, executed 5 separate purchases totaling 28,856 shares for $23,204.80 on September 9-10, 2024, bringing his holdings from zero to 28,856 shares and establishing a new position. This activity occurred within a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated or contemporaneous confidence in the stock. The purchase prices ($0.71–$0.91 across transactions) represent a blended average of $0.80, which is 66.3% below the current price of $23.71 and reflects aggressive buying into a stock trading 88.4% below its 52-week high of $204.05. However, the company reported a negative full-year net income of $-1,974,033.00, indicating ongoing unprofitability, which contextualizes the risk profile of this newly accumulated position.

COO Carter bought 37,735 shares (37.7K) across 4 transactions for $28,737.13, raising stake to 47,092 shares at blended avg $0.76 while stock down 87.0% from 52-week high

Carter Denise P., Chief Operating Officer, executed 4 separate purchase transactions totaling 37,735 shares for $28,737.13 at an average price of $0.76, expanding holdings by 403.3% from 9,357 to 47,092 shares. The purchases occurred on 2024-09-03 and 2024-09-04 at prices ranging from $0.63 to $0.80. This substantial accumulation is notable given the stock's sharp decline of 87.0% from its 52-week high of $215.60 to current price of $27.91, alongside company unprofitability (net income of $-2.0M). The magnitude of the COO's position increase, particularly at these depressed price levels shortly after a steep drawdown, warrants tracking of whether the executive action reflects conviction about recovery prospects or structural changes within the organization.

CEO Myers buys 37,894 shares across 4 transactions (Sep 3–4) for $28,916.10 at avg $0.76; stock now $27.91 post 45.8% 30-day rise from depressed levels.

Michael Myers, Chief Executive Officer, executed four separate purchases totaling 37,894 shares for $28,916.10 between September 3-4, 2024, at prices ranging from $0.62 to $0.80, expanding his holdings by 404.9% from 9,358 to 47,252 shares. The company is currently unprofitable with net income of $-1,974,033.00 over its most recent fiscal year, and the stock is -87.0% below its 52-week high of $215.60, though it has recovered +45.8% over the past 30 days. The magnitude and concentrated timing of this CEO purchase across four separate transactions provides a substantive data point on insider capital allocation in a deeply distressed equity, but the negative fundamentals and extreme drawdown from prior peaks limit the confidence signal.